TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03538860

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Active comparator: Human interpreter
Description: A Spanish-speaking patient is diagnostically assessed in-person by an English-speaking psychiatrist through a Spanish-speaking interpreter.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Active comparator: Human interpreter
Description: A Spanish-speaking patient is diagnostically assessed in-person by an English-speaking psychiatrist through a Spanish-speaking interpreter.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intervention: Asynchronous Telepsychiatry
Description: A Spanish-speaking patient is interviewed in Spanish by a trained mental health interviewer. The interview is video-recorded in real-time, automatically translated into English with sub-titles added to the video file, and sent to a psychiatrist and to 3 English-speaking psychiatrists to asynchronously review the video and make a diagnosis.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intervention: Asynchronous Telepsychiatry
Description: A Spanish-speaking patient is interviewed in Spanish by a trained mental health interviewer. The interview is video-recorded in real-time, automatically translated into English with sub-titles added to the video file, and sent to a psychiatrist and to 3 English-speaking psychiatrists to asynchronously review the video and make a diagnosis.
Study: NCT04341493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide 500 MG
Description: Clinical evaluation of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using this option with two drugs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Clinical evaluation of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using this option with one drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Clinical evaluation of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using this option with one drug
Study: NCT03981380

Intervention type: DRUG
Intervention: 11C-PIB
Description: Participants will be injected with an intravenous bolus of up to 5-15mCi (370 MBq) (+/-10%) of \[11C\]PiB (over 5-10 seconds).
Study: NCT03790501

Intervention type: OTHER
Intervention: No intervention
Description: As an observational study, no intervention will be associated with the study group.
Study: NCT01487395

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil .
Description: Donepezil will be administered OS as of 5 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the placebo will be administered OS as of 5 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.
Study: NCT03895008

Intervention type: OTHER
Intervention: Cardia and Non-cardia gastric cancer
Description: We classify gastric cancer into cardia gastric cancer and non-cardia gastric cancer.

Intervention type: OTHER
Intervention: Cardia and Non-cardia gastric cancer
Description: We classify gastric cancer into cardia gastric cancer and non-cardia gastric cancer.
Study: NCT04005404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine (sciatic nerve block)
Description: injection of 20 ml ropivacaine 0.375%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine (sciatic nerve block)
Description: injection of 20 ml ropivacaine 0.375%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine (sciatic nerve block)
Description: injection of 20 ml ropivacaine 0.375%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine (lumbar plexus block L2-L4)
Description: injection of 20 ml ropivacaine 0.375%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine (lumbar plexus block L2-L4)
Description: injection of 20 ml ropivacaine 0.375%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine (lumbar plexus block L2-L4)
Description: injection of 20 ml ropivacaine 0.375%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine (lumbar plexus block Th12-L1)
Description: injection of 20 ml ropivacaine 0.375%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine (lumbar plexus block Th12-L1)
Description: injection of 20 ml ropivacaine 0.375%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine (lumbar plexus block Th12-L1)
Description: injection of 20 ml ropivacaine 0.375%
Study: NCT00753285

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal Denervation
Study: NCT00660257

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pandemic influenza vaccine (H5N1 strain NIBRG-14)
Description: pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 1.25 ug per dose, intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pandemic influenza vaccine (H5N1 strain NIBRG-14)
Description: pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 2.5 ug per dose, intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pandemic influenza vaccine (H5N1 strain NIBRG-14)
Description: pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 5.0 ug per dose, intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pandemic influenza vaccine (H5N1 strain NIBRG-14)
Description: pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 1.25 ug per dose, intramuscular injection
Study: NCT01237171

Intervention type: RADIATION
Intervention: Cesium-131 Brachytherapy Seed
Description: 85 Gray Dose
Study: NCT01227590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kaletra (lopinavir/ritonavir), African Potato (hypoxis obtusa)
Description: The baseline PK of LPV/r will be established after 14 days of taking LPV/r at a dose of 400/100 mg twice daily. This will be followed by a 7 day course of LPV/r and AP together. The AP dose to be administered will be 15 mg/kg/day of hypoxoside.
Study: NCT01277627

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine
Description: nevirapine: 400 mg a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine
Description: nevirapine: 400 mg a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz, protease inhibitors
Description: efavirenz: 600 mg a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz, protease inhibitors
Description: efavirenz: 600 mg a day
Study: NCT01074801

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Closed-loop insulin delivery
Description: Basal subcutaneous insulin delivery to be adjusted at 15min cycles according to the computer-based algorithm advice.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard insulin pump treatment
Description: Subcutaneous insulin delivery to be performed based on subjects' standard treatment
Study: NCT02037178

Intervention type: OTHER
Intervention: First ultrasound reading
Description: First ultrasound reading of the sub-renal abdominal aorta by a general practitioner.

Intervention type: OTHER
Intervention: Second ultrasound interpretation
Description: The untrasound images recorded by general practitioners will be interpreted a second time by an expert in vascular medecine, and evaluated for their image quality.
Study: NCT04412655

Intervention type: DEVICE
Intervention: Percutaneous Coronary Revascularization for STEMI
Description: Percutaneous Mechanical Reperfusion for STEMI

Intervention type: DEVICE
Intervention: Percutaneous Coronary Revascularization for STEMI
Description: Percutaneous Mechanical Reperfusion for STEMI
Study: NCT00317187

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix-HepB/Meningitec conjugate vaccine
Description: The full content of two monodose vials of Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Meningitec (5/5/5) vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): one dose of 0.5 ml of the reconstituted Tritanrix- HepB/Meningitec vaccine was withdrawn from the vial and administered, the needle was changed before injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix-HepB/Meningitec conjugate vaccine
Description: The full content of two monodose vials of Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Meningitec (5/5/5) vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): one dose of 0.5 ml of the reconstituted Tritanrix- HepB/Meningitec vaccine was withdrawn from the vial and administered, the needle was changed before injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix-HepB/Meningitec conjugate vaccine
Description: The full content of two monodose vials of Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Meningitec (5/5/5) vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): one dose of 0.5 ml of the reconstituted Tritanrix- HepB/Meningitec vaccine was withdrawn from the vial and administered, the needle was changed before injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tritanrix/Hiberix vaccine
Description: The full content of the Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Hiberix vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): the full volume of the mixed vaccines was withdrawn from the vial, the needle was changed before injection.
Study: NCT00462709

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C1 esterase inhibitor [human] (C1INH-nf)
Study: NCT02531308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin upregulates AMPK activity which has been shown to have an anti-proliferative effect on lymphoma cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: monoclonal antibody against protein CD20 primarily found on the surface of B-cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Interferes with DNA replication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: anthracycline antitumor antibiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Inhibits cell mitosis causing cell death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: a synthetic corticosteroid drug that is particularly effective as an immunosuppressant drug. It is used to treat certain inflammatory diseases

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: stimulates the level of white blood cells (neutrophils).
Study: NCT02180529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: On the intervention days (days 2-4) participants will undergo cognitive assessment at 9:00 in the morning, followed by the administration (at 10:30) of different doses of Ritalin (10, 20 and 30mg) every day of intervention.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02646540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan 30 mg + IV Diuretics
Description: Participants will receive oral daily tolvaptan 30 mg concomitantly with their standard dose of intravenous (IV) diuretics for the duration of their hospitalization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metolazone 5 mg + IV Diuretics
Description: Participants will receive oral daily metolazone 5 mg concomitantly with their standard dose of intravenous (IV) diuretics for the duration of their hospitalization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2.5 times the Diuretics Dose
Description: Participants will receive two and a half (2.5) times their standard dose of intravenous (IV) diuretics for the duration of their hospitalization.
Study: NCT03608033

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OMS721
Description: Biological: OMS721

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle (D5W or saline)
Description: 5% Dextrose in water or normal saline solution
Study: NCT02364830

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anise-oil EC Capsule
Description: Anise-oil EC Capsule,One Cap(187mg)/day for 4 Weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One Placebo Capsule/Day for 4 Weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colpermin®
Description: Colpermin® Capsule/Day for 4 Weeks
Study: NCT04394234

Intervention type: DRUG
Intervention: Direct oral anticoagulant (DOACs)
Description: Data of participants newly exposed to individual DOACs that is rivaroxaban, apixaban, dabigatran from 19-Oct-2010 to 31-Dec-2018 will be assessed. No study drug treatment will be administered as part of this observational study.

Intervention type: DRUG
Intervention: Direct oral anticoagulant (DOACs)
Description: Data of participants newly exposed to individual DOACs that is rivaroxaban, apixaban, dabigatran from 19-Oct-2010 to 31-Dec-2018 will be assessed. No study drug treatment will be administered as part of this observational study.

Intervention type: DRUG
Intervention: Warfarin
Description: Data of participants newly exposed to warfarin from 19-Oct-2010 to 31-Dec-2018 will be assessed. No study drug treatment will be administered as part of this observational study.
Study: NCT02318680

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Review of follow home visits after discharge from Nykøbing Falster Hospital
Description: The intervention is follow home visits which is randomized and is an intervention that is assigned by the investigator.
Study: NCT01599260

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Two 30-minute individually supervised exercise sessions per week for 16-weeks
Study: NCT03107390

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluate the blood level of NTproBNP
Description: Evaluate the blood level of NTproBNP in patients with MICI compared to a healthy control population.

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluate the blood level of NTproBNP
Description: Evaluate the blood level of NTproBNP in patients with MICI compared to a healthy control population.
Study: NCT02989870

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Participants will receive 3-5 fractions of radiation as determined by the dose level at time of enrollment. The starting dose level will be Dose Level 1: 8 Gy x 3 fractions for a total of 24 Gy. If sufficient treatment related toxicity is observed at the initial starting dose, then the dose will be reduced to 16 Gy in 2 fractions of 8 Gy. The dose per fraction for each participant will be provided at the time of registration based on the toxicity experience of the previous participants on study. This will be escalated to 40 Gy in 5 fractions of 8 Gy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib by mouth (PO): 200 mg twice a day (BID) then 400 mg BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bavituximab
Description: Bavituximab intravenously (IV): 3 mg/kg every week (q wk).
Study: NCT04168723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MD1003
Description: Group A: Daily dose of 1200 mg of MD1003 from Day 1 to Day 8

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400mg
Description: Group B1: Moxifloxacin 400 mg on Day 1 Group B2: Moxifloxacin 400 mg on Day 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for MD1003
Description: Group A: Placebo for MD1003 on Day -1 Group B1: Placebo for MD1003 on Day -1 Group B2: Placebo for MD1003 on Day -1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for MD1003
Description: Group A: Placebo for MD1003 on Day -1 Group B1: Placebo for MD1003 on Day -1 Group B2: Placebo for MD1003 on Day -1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for moxifloxacin
Description: Group A: Placebo for moxifloxacin on Day 1 and Day 9 Group B1: Placebo for moxifloxacin on Day 9 Group B2: Placebo for moxifloxacin on Day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for moxifloxacin
Description: Group A: Placebo for moxifloxacin on Day 1 and Day 9 Group B1: Placebo for moxifloxacin on Day 9 Group B2: Placebo for moxifloxacin on Day 1
Study: NCT01226966

Intervention type: DRUG
Intervention: liraglutide
Description: Prescription is done at the discretion of the prescribing physician as part of normal clinical routine.
Study: NCT00002772

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT01867125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Lebrikizumab will be administered as SC injection at 125 or 37.5 mg every 4 weeks, for 104 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Lebrikizumab will be administered as SC injection at 125 or 37.5 mg every 4 weeks, for 104 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lebrikizumab
Description: Lebrikizumab will be administered as SC injection at 125 or 37.5 mg every 4 weeks, for 104 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lebrikizumab matching placebo will be administered as SC injection every 4 weeks for 52 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lebrikizumab matching placebo will be administered as SC injection every 4 weeks for 52 weeks.
Study: NCT04380935

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Description: Convalescent plasma of recovered COVID-19 patients (donor)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: According to national or hospital guidelines COVID-19 Management Protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: According to national or hospital guidelines COVID-19 Management Protocol
Study: NCT00813384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 208
Description: AMG 208 is a small molecule inhibitor of c-Met which is a well-characterized receptor tyrosine kinase expressed on the surface of epithelial cells. C-Met receptor signaling has been shown to play a key role in the survival of cancer cells. AMG 208 inhibits both ligand-dependent and ligand-independent c-Met cellular growth regulation. Inhibition of c-Met signaling with AMG 208 provides a potential mechanism for blocking tumor growth and survival.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 208
Description: AMG 208 is a small molecule inhibitor of c-Met which is a well-characterized receptor tyrosine kinase expressed on the surface of epithelial cells. C-Met receptor signaling has been shown to play a key role in the survival of cancer cells. AMG 208 inhibits both ligand-dependent and ligand-independent c-Met cellular growth regulation. Inhibition of c-Met signaling with AMG 208 provides a potential mechanism for blocking tumor growth and survival.
Study: NCT02499211

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention stores
Description: In-store marketing strategies will focus on placement and promotion of healthier items (lower calorie options) in the milk, frozen food, beverage checkout cooler, bread, salty snacks, and cheese sections of the store.~Intervention efforts in the dairy section promote lower calorie milk (skim, 1%, and 2%), while diminishing the presence of whole milk. The visual order of the milk displays will be changed, and the number of facings, or the fronts of packages the consumer can see, of whole milk will be decreased by 30% while increasing the facings of the lower calorie milk. In the other product categories, target products will be moved to eye level and the number of facings will be increased.~Call-out signs will be placed by the target products that list the name and price of the product. No health information or claims will be included. Signage will be rotated monthly to increase the chances that customers will notice them.
Study: NCT01396135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-601,927
Description: Single dose of 1 mg CP-601,927 given as oral 1 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-601,927
Description: Single dose of 2 mg CP-601,927 given as oral 1 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-601,927
Description: Single dose of 3 mg CP-601,927 given as oral 1 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of placebo given as a matching number of oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-601,927
Description: Multiple doses of CP-601,927 given as 2 mg BID (4 mg/day) as oral 1 mg tablets for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multiple doses of placebo given as a matching number of oral tablets
Study: NCT02840123

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous dendritic cells
Study: NCT03191318

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ERAS pathway
Description: ERAS pathway after laparoscopic sleeve gastrectomy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard pathway
Description: Standard pathway after laparoscopic sleeve gastrectomy